EP4665341A1 - Fgfr-tyrosinkinasehemmer zur behandlung von risikoreichem nicht-muskelinvasivem blasenkrebs - Google Patents

Fgfr-tyrosinkinasehemmer zur behandlung von risikoreichem nicht-muskelinvasivem blasenkrebs

Info

Publication number
EP4665341A1
EP4665341A1 EP24705399.4A EP24705399A EP4665341A1 EP 4665341 A1 EP4665341 A1 EP 4665341A1 EP 24705399 A EP24705399 A EP 24705399A EP 4665341 A1 EP4665341 A1 EP 4665341A1
Authority
EP
European Patent Office
Prior art keywords
ranges
treatment
erdafitinib
fgfr3
nmibc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24705399.4A
Other languages
English (en)
French (fr)
Inventor
Mahadi Ali BAIG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of EP4665341A1 publication Critical patent/EP4665341A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP24705399.4A 2023-02-13 2024-02-12 Fgfr-tyrosinkinasehemmer zur behandlung von risikoreichem nicht-muskelinvasivem blasenkrebs Pending EP4665341A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363445180P 2023-02-13 2023-02-13
US202363590352P 2023-10-13 2023-10-13
PCT/EP2024/053475 WO2024170495A1 (en) 2023-02-13 2024-02-12 Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Publications (1)

Publication Number Publication Date
EP4665341A1 true EP4665341A1 (de) 2025-12-24

Family

ID=89942584

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24705399.4A Pending EP4665341A1 (de) 2023-02-13 2024-02-12 Fgfr-tyrosinkinasehemmer zur behandlung von risikoreichem nicht-muskelinvasivem blasenkrebs

Country Status (8)

Country Link
EP (1) EP4665341A1 (de)
KR (1) KR20250148646A (de)
CN (1) CN120813357A (de)
AU (1) AU2024222187A1 (de)
IL (1) IL322665A (de)
MX (1) MX2025009445A (de)
TW (1) TW202448471A (de)
WO (1) WO2024170495A1 (de)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP1904480A2 (de) 2005-05-23 2008-04-02 Novartis Pharma AG Kristalline und andere formen von 4-amino-5-fluor-3-[6-(methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-chinolin-2-onmilchsäuresalz
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
MX392774B (es) 2014-09-26 2025-03-24 Janssen Pharmaceutica Nv Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderán al tratamiento con un inhibidor fgfr
CA3162962A1 (en) * 2020-02-12 2021-08-19 Manish MONGA Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Also Published As

Publication number Publication date
AU2024222187A1 (en) 2025-10-02
WO2024170495A1 (en) 2024-08-22
IL322665A (en) 2025-10-01
CN120813357A (zh) 2025-10-17
KR20250148646A (ko) 2025-10-14
TW202448471A (zh) 2024-12-16
MX2025009445A (es) 2025-11-03

Similar Documents

Publication Publication Date Title
US20230110113A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
US20220175768A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
WO2018141921A1 (en) Cancer treatment
EP3576740A1 (de) Krebsbehandlung
JP2025156297A (ja) 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
US20250000858A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
WO2024170495A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
CN117320724A (zh) 用于治疗晚期实体瘤的fgfr酪氨酸激酶抑制剂
HK40064235A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40081735A (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE